Loading…
← CockpitCompetitor Analysis › RLMD Relmada Therapeutics IncOpen in the cockpit ↗

Relmada Therapeutics IncRLMDCompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major
Momentum laggard 9
Mkt cap
$305M
US dollars, full cap
Free float
87%
of shares outstanding
$/day
$6.79M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 8.1%
Hurdle
n/a
no reverse DCF
Next earnings
125 days
23 Mar 2027
Close · USD$2.85
1D-5.2%
1W-35.5%
1M-15.0%
3M-38.5%
6M-60.2%
YTD-40.9%
1Y-28.1%
ATR %12.8%
Beta1.87
52w lowhigh64.3% off high

What Relmada Therapeutics does

Employees: 17

Relmada Therapeutics at a glance

Size Relmada Therapeutics (RLMD) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $305M, the 3068th largest of 3,085 United States companies the cockpit tracks. Shares closed at $2.85 on 18 Nov 2026.

Performance Over six months the shares fell 60.2%, against -20.9% for the median peer and -2.2% for the United States market (cap-weighted) — lowest of 21 in its peer set.

Next results Next results expected around 23 Mar 2027 (exchange calendar; dates can move).

Relative performance

40608010021 May 202621 Aug 202618 Nov 2026Peer median 77RLMD 40
Six months, rebased to 100: Relmada Therapeutics against the median of its 20 peers (local-currency closes).

Relmada Therapeutics financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$0$0$0$0$0
Revenue growth—————
Gross profit$0$0$0$0$0
EBITDA-$67.9M-$59.1M-$83.9M-$104M-$161M
Net income-$65.7M-$57.4M-$80.0M-$98.8M-$157M
Free cash flow-$51.9M-$45.8M-$51.8M-$51.7M-$104M
Capital expenditure$0$0$0$0$0
Total debt$0$0$0$0$0

Quarterly statements and history in the cockpit →

Relmada Therapeutics competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%0%+20%688302301331ALEMBICLTD300086000790603079605199INDSWFTLAB4174INO368A3005830052501720RLMD6-month return →1-month return →
Up and to the right = strong over both horizons. Relmada Therapeutics is the large dot.

Relmada Therapeutics competitors and peer comparison

How Relmada Therapeutics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Relmada Therapeutics against its 20 peers (data as of 18 Nov 2026)
MeasureRLMDPeer medianRank in peer set
1-month return-15.0%-9.4%2nd lowest of 21
6-month return-60.2%-20.9%lowest of 21
Distance from 52-week high-64.3%-37.5%2nd lowest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Relmada Therapeutics RLMDUnited States$305M-60%n/an/an/an/an/a
Hinova Pharmaceuticals 688302.SSChina$305M-35%+251%-195%17.1×n/an/a
Enwei Pharmaceutical 301331.SZChina$308M-20%-7%5%2.1×14.0%+7.3%
Alembic ALEMBICLTD.NSIndia$309M+25%-5%26%13.0×44.3%+26.7%
Honz Pharmaceutical 300086.SZChina$299M-40%-23%-54%7.3×56.0%-12.8%
Chengdu Huasun Technology 000790.SZChina$312M-20%-36%-57%5.6×27.5%-6.4%
Zhejiang Shengda Bio-Pharm 603079.SSChina$297M-30%-3%7%2.3×4.6%-0.3%
Hainan Huluwa Pharmaceutical 605199.SSChina$296M-21%-32%-58%4.8×1.4%-4.9%
Ind-Swift Laboratories INDSWFTLAB.NSIndia$314M+150%+66%9%3.4×n/an/a
OBI Pharma 4174.TWOTaiwan$295M+135%-2%-2,968%214.0×n/an/a
Inovio Pharmaceuticals INOUnited States$317M+37%+64%-25,954%921.6×n/an/a
Kitazato 368A.TJapan$317M+7%+9%52%3.1×-16.8%+5.4%
Shandong Sito Bio-technology 300583.SZChina$292M-30%+19%6%2.3×1.6%+2.3%
Atea Pharmaceuticals AVIRUnited States$320M-5%n/an/an/an/an/a
GC Corp. 005250.KSSouth Korea$321M-45%+2%3%1.1×n/an/a
Swedencare SECARE.STSweden$321M-24%+3%7%1.8×6.1%+62.1%
Foresee Pharmaceuticals 6576.TWOTaiwan$322M-12%+6%-104%21.4×n/an/a
Beihai Gofar Chuanshan Biological 600538.SSChina$326M-39%+10%-8%6.2×n/an/a
Chongqing Hifuture Information Technology 002168.SZChina$326M-27%+2%-6%7.4×14.3%-14.0%
Standard Chemical & Pharmaceutical 1720.TWTaiwan$329M-1%+5%22%1.8×-11.5%+10.3%
Kingchem (Liaoning) Life Science 301509.SZChina$333M-28%+3%6%1.4×9.2%+6.5%

Questions

Which companies are Relmada Therapeutics's closest peers?
The cockpit's peer set: Hinova Pharmaceuticals (688302.SS), Enwei Pharmaceutical (301331.SZ), Alembic (ALEMBICLTD.NS), Honz Pharmaceutical (300086.SZ), Chengdu Huasun Technology (000790.SZ), Zhejiang Shengda Bio-Pharm (603079.SS), Hainan Huluwa Pharmaceutical (605199.SS), Ind-Swift Laboratories (INDSWFTLAB.NS).
How has Relmada Therapeutics stock performed?
Over six months to 18 Nov 2026 the shares returned -60.2% against -20.9% for the median peer; over one year -28.1%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.